K
Kim A. Eagle
Researcher at University of Michigan
Publications - 852
Citations - 85694
Kim A. Eagle is an academic researcher from University of Michigan. The author has contributed to research in topics: Aortic dissection & Myocardial infarction. The author has an hindex of 129, co-authored 823 publications receiving 75160 citations. Previous affiliations of Kim A. Eagle include University of Wisconsin Hospital and Clinics & Spaulding Rehabilitation Hospital.
Papers
More filters
Journal ArticleDOI
Effect of a promotional campaign on heart-healthy menu choices in community restaurants.
TL;DR: It is indicated that dietetics professionals must continue to develop strategies to promote heart-healthy food choices in community restaurants as a trend toward a slight increase in heart- healthy menu item selections is shown.
Journal ArticleDOI
Cardiac risk of noncardiac surgery.
Kim A. Eagle,Charles A. Boucher +1 more
TL;DR: This review focuses on important features of the initial pre-operative clinical risk assessment, indications for diagnostic testing to quantify cardiac risk, and the methods and indications for pre-emptive therapies.
Journal ArticleDOI
Do gender-based differences in presentation and management influence predictors of hospitalization costs and length of stay after an acute myocardial infarction?
Sumita D. Paul,Sumita D. Paul,Kim A. Eagle,Kim A. Eagle,Ursula Guidry,Ursula Guidry,Thomas G. DiSalvo,Thomas G. DiSalvo,Gerardo Villarreal-Levy,Gerardo Villarreal-Levy,A.J. Conrad Smith,A.J. Conrad Smith,Christopher J. O'Donnell,Christopher J. O'Donnell,Zakwan A. Manjoub,Zakwan A. Manjoub,Visala Muluk,Visala Muluk,John B. Newell,John B. Newell,Patrick T. O'Gara,Patrick T. O'Gara +21 more
TL;DR: Women were older, had systemic hypertension, diabetes mellitus, and a non-Q-wave AMI more frequently, whereas more men smoked cigarettes, and cost during hospitalization for men were pulmonary edema, coronary angiography, intraaortic balloon pump use, and coronary bypass; for women, they were peak levels of creatine kinase and heart failure.
Journal ArticleDOI
Thiazolidinediones in Type 2 Diabetes: A Cardiology Perspective
TL;DR: Although the glycemic efficacy of TZDs is comparable to that of metformin, ad verso effects and higher costs make TZD less appealing for initial therapy and pioglitazone should be considered based on cardiovascular safety data.